New development of lipid-lowering therapy of coronary heart disease: Evinacumab
10.12092/j.issn.1009-2501.2022.04.001
- Author:
Qi WANG
1
;
Yunzeng ZOU
2
Author Information
1. Department of General Medicine, Zhongshan Hospital of Fudan University
2. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases
- Publication Type:Journal Article
- Keywords:
Coronary heart disease;
Evinacumab;
Lipid-lowering therapy;
The latest advances
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(4):362-364
- CountryChina
- Language:Chinese
-
Abstract:
Homozygous familial hypercholesterolemia is a rare genetic disorder of lipid metabolism, traditional lipid-lowering therapies such as statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have little efficacy in these patients. Evinacumab can reduce the levels of LDL-C effectively. In this review, we summarize the latest advances in Evinacumab, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Evinacumab. Finally, we discuss the current status of Evinacumab in the clinical works.
